Sona Nanotech Inc C.SONA

RE:RE:Awaiting Response From Manufacturer

[JoeScotia]

There is evidence to indicate that the two South Korean tests on HC’s list of antigen test applications that are awaiting response from manufacturer could be in a lot of trouble. I know the wait for validation of Sona’s test was difficult for all investors but I expect hindsight will show that 3rd party validation was a brilliant move on the part of Sona’s management. I can not find any evidence that either of the Korean tests was 3rd party validated.

The Biocredit Covid-19 Ag test from Rapigen Inc. (South Korea) is in HC’s “awaiting response” status. The Journal of Clinical Virology did a study on the test and found it only detected 11.1% to 45.7% from RT-PCR positive samples from Covid-19 patients. Furthermore it’s LOD was deemed to be a 1,000 times less sensitive than a viral culture and 1,000,000 times less sensitive than a RT-PCR test. Major red flags for any regulator. https://www.sciencedirect.com/science/article/pii/S1386653220302420

The Standard Q COVID-19 AG Test from SD Biosensor, Inc. (Korea) is also in HC’s “awaiting response” status. The WHO said they were going to buy 120M tests (SD Biosensor and Abbott’s BinaxNow) in their Sept 28 press release https://www.who.int/news-room/detail/28-09-2020-global-partnership-to-make-available-120-million-affordable-quality-covid-19-rapid-tests-for-low--and-middle-income-countries. Then this article said it failed evaluation “because it fell short of World Health Organization (WHO) standards". Furthermore, it “only posted 71% sensitivity” when the WHO has a minimum sensitivity standard of 80%. https://www.msn.com/en-ph/news/national/sd-biosensor-covid-19-antigen-test-fails-doh-evaluation/ar-BB19yzZv and https://cnnphilippines.com/news/2020/9/30/SD-Biosensor-rapid-antigen-test-kit-RITM-study-COVID-19.html